Compare Gilead Sciences, Inc. (GILD) vs Lucid Group Inc (LCID) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Lucid Group Inc — how do they compare? Gilead Sciences, Inc. trades at $133.5 (market cap $163.51B), while Lucid Group Inc trades at $6.7 (market cap $2.32B). The key difference: Gilead Sciences, Inc. is far larger — about 70.5× Lucid Group Inc's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Lucid Group Inc pays none. Which is the better fit depends on your goals.
| GILD | LCID | |
|---|---|---|
Market Cap | $163.51B | $2.32B |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $31.30 |
52-Week Low | $108.22 | $4.62 |
Enterprise Value | $178.05B | $4.79B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Lucid Group (LCID) trades at $6.66, up 44.16% in the last session following CEO denial of bankruptcy rumors. The stock shows a neutral technical signal with bullish moving averages but negative oscillators. Fundamentally, the company reports a net loss of $2.70B on $1.35B revenue for 2025, with negative margins across gross profit (-95.6%) and net income (-239.81%). Cash flow remains negative at -$566.14M, though liquidity is claimed sufficient into 2026.
Outlook is highly speculative with significant execution risks. While the recent price surge reflects relief from bankruptcy fears, persistent cash burn, missed earnings, and class-action lawsuits pose substantial downside. Analyst consensus is cautious with a $10.50 price target but only 13.33% buy ratings. Investment hinges on successful midsize EV launch and cost control amid intense competition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Lucid Group Inc
Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It is a vertically integrated company that designs, engineers, and builds electric vehicles, EV powertrains, and battery systems in-house using our own equipment and factory.
Read more on LCID →
